AKT1 and acute myeloid leukemia: Hyperactivation of PI3K/Akt/mTOR has been associated with attenuated sensitivity to chemotherapy and growing evidence suggests that targeting key components of this pathway may represent an effective treatment to kill AML LSCs [14].